Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma, Renal Cell 2Advanced Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Folfox protocol 18Cisplatin 18IFL protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × abemaciclib × Clear all
NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
210 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡